angiotensin II

This medicine is authorised for use in the European Union.


Giapreza is a medicine used in adults with dangerously low blood pressure (a condition known as shock).

It is used when other treatments for raising blood pressure have not worked and contains the active substance angiotensin II.

This EPAR was last updated on 24/03/2023

Authorisation details

Product details
Agency product number
Active substance
Angiotensin II acetate
International non-proprietary name (INN) or common name
angiotensin II
Therapeutic area (MeSH)
  • Hypotension
  • Shock
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
PAION Deutschland GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Heussstraße 25
52078 Aachen

Product information

23/03/2023 Giapreza - EMEA/H/C/004930 - IAIN/0023

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.

Assessment history

How useful was this page?

Add your rating
2 ratings